Your browser doesn't support javascript.
loading
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
Brennan, Xavier; Withers, Barbara; Jabbour, Andrew; Milliken, Sam; Kotlyar, Eugene; Fay, Keith; Ma, David; Muthiah, Kavitha; Hamad, Nada; Dodds, Anthony; Bart, Nikki; Keogh, Anne; Hayward, Chris; Macdonald, Peter; Moore, John.
Afiliação
  • Brennan X; Cardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Withers B; University of New South Wales, Sydney, New South Wales, Australia.
  • Jabbour A; Department of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Milliken S; Cardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Kotlyar E; University of New South Wales, Sydney, New South Wales, Australia.
  • Fay K; The Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia.
  • Ma D; University of New South Wales, Sydney, New South Wales, Australia.
  • Muthiah K; Department of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Hamad N; Cardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Dodds A; Department of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Bart N; Department of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Keogh A; Cardiology Department, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • Hayward C; University of New South Wales, Sydney, New South Wales, Australia.
  • Macdonald P; University of New South Wales, Sydney, New South Wales, Australia.
  • Moore J; Department of Haematology and Bone Marrow Transplant, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Intern Med J ; 52(10): 1826-1830, 2022 10.
Article em En | MEDLINE | ID: mdl-36266066
Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose Idioma: En Ano de publicação: 2022 Tipo de documento: Article